Women with PsA at risk for adverse pregnancy outcomes

Key clinical point: Pregnant women with psoriatic arthritis (PsA), particularly those requiring antirheumatic treatment, are at increased risk for adverse pregnancy outcomes.

Major finding: Pregnancy in PsA vs. non-PsA women were associated with increased risk for preterm birth (adjusted odds ratio [aOR] 1.69; 95% CI 1.27-2.24), elective cesarean delivery (CD; aOR 1.77; 95% CI 1.43-2.20), and emergency CD (aOR 1.42; 95% CI 1.10-1.84) with the risk even more pronounced in pregnancies in women with PsA with exposure to antirheumatic treatment any time before or during pregnancy (preterm birth: aOR 1.98; 95% CI 1.27-2.86; elective CD: aOR 1.96; 95% CI 1.47-2.63; and emergency CD: aOR 1.67; 95% CI 1.18-2.36).

Study details: This was a cohort study including 921 pregnancies in patients with PsA matched with 9,210 pregnancies in non-PsA patients.

Disclosures: This study did not receive any funding. None of the authors declared any conflict of interests.

Source: Remaeus K et al. Arthritis Rheumatol. 2021 (Oct 20). Doi: 10.1002/art.41985.

Key clinical point: Pregnant women with psoriatic arthritis (PsA), particularly those requiring antirheumatic treatment, are at increased risk for adverse pregnancy outcomes.

Major finding: Pregnancy in PsA vs. non-PsA women were associated with increased risk for preterm birth (adjusted odds ratio [aOR] 1.69; 95% CI 1.27-2.24), elective cesarean delivery (CD; aOR 1.77; 95% CI 1.43-2.20), and emergency CD (aOR 1.42; 95% CI 1.10-1.84) with the risk even more pronounced in pregnancies in women with PsA with exposure to antirheumatic treatment any time before or during pregnancy (preterm birth: aOR 1.98; 95% CI 1.27-2.86; elective CD: aOR 1.96; 95% CI 1.47-2.63; and emergency CD: aOR 1.67; 95% CI 1.18-2.36).

Study details: This was a cohort study including 921 pregnancies in patients with PsA matched with 9,210 pregnancies in non-PsA patients.

Disclosures: This study did not receive any funding. None of the authors declared any conflict of interests.

Source: Remaeus K et al. Arthritis Rheumatol. 2021 (Oct 20). Doi: 10.1002/art.41985.

Key clinical point: Pregnant women with psoriatic arthritis (PsA), particularly those requiring antirheumatic treatment, are at increased risk for adverse pregnancy outcomes.

Major finding: Pregnancy in PsA vs. non-PsA women were associated with increased risk for preterm birth (adjusted odds ratio [aOR] 1.69; 95% CI 1.27-2.24), elective cesarean delivery (CD; aOR 1.77; 95% CI 1.43-2.20), and emergency CD (aOR 1.42; 95% CI 1.10-1.84) with the risk even more pronounced in pregnancies in women with PsA with exposure to antirheumatic treatment any time before or during pregnancy (preterm birth: aOR 1.98; 95% CI 1.27-2.86; elective CD: aOR 1.96; 95% CI 1.47-2.63; and emergency CD: aOR 1.67; 95% CI 1.18-2.36).

Study details: This was a cohort study including 921 pregnancies in patients with PsA matched with 9,210 pregnancies in non-PsA patients.

Disclosures: This study did not receive any funding. None of the authors declared any conflict of interests.

Source: Remaeus K et al. Arthritis Rheumatol. 2021 (Oct 20). Doi: 10.1002/art.41985.